{
  "attach_pages": "4",
  "attach_size": "794",
  "attach_type": "0",
  "attach_url": "https://pdf.dfcfw.com/pdf/H3_AP201805021134453679_1.pdf?1525254380000.pdf",
  "company_code": "10000296",
  "eitime": "2018-05-02 09:46:38",
  "extend": {},
  "info_code": "AP201805021134453679",
  "language": "0",
  "notice_date": "2018-05-02 00:00:00",
  "notice_title": "内生增长强劲，抵消国药业绩下滑负面影响",
  "page_size": 1,
  "page_size_ch": 0,
  "page_size_cht": 0,
  "page_size_en": 0,
  "rating": "A",
  "researcher": "朱国广",
  "security": [
    {
      "market_uni": "1",
      "publish_relation": [
        {
          "originalCode": "465",
          "publishName": "化学制药"
        }
      ],
      "short_name": "复星医药",
      "short_name_ch": "复星医药",
      "short_name_cht": "復星醫藥",
      "short_name_en": "FOSUN PHARMA",
      "stock": "600196"
    }
  ],
  "short_name": "复星医药",
  "source_sample_name": "西南证券",
  "star": "3"
}